25 XP   0   0   10

Galmed Pharmaceuticals Ltd
Buy, Hold or Sell?

Let's analyse Galmed Pharmaceuticals Ltd together

PenkeI guess you are interested in Galmed Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Galmed Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Galmed Pharmaceuticals Ltd

I send you an email if I find something interesting about Galmed Pharmaceuticals Ltd.

Quick analysis of Galmed Pharmaceuticals Ltd (30 sec.)










What can you expect buying and holding a share of Galmed Pharmaceuticals Ltd? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.49
Expected worth in 1 year
$1.05
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-1.44
Return On Investment
-436.6%

For what price can you sell your share?

Current Price per Share
$0.33
Expected price per share
$0.26 - $0.35
How sure are you?
50%

1. Valuation of Galmed Pharmaceuticals Ltd (5 min.)




Live pricePrice per Share (EOD)

$0.33

Intrinsic Value Per Share

$-38.58 - $27.99

Total Value Per Share

$-36.09 - $30.48

2. Growth of Galmed Pharmaceuticals Ltd (5 min.)




Is Galmed Pharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$15.5m$24.3m-$11.4m-89.2%

How much money is Galmed Pharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$1.8m-$6m$4.1m217.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Galmed Pharmaceuticals Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#629 / 1031

Most Revenue
#948 / 1031

Most Profit
#311 / 1031

Most Efficient
#402 / 1031

What can you expect buying and holding a share of Galmed Pharmaceuticals Ltd? (5 min.)

Welcome investor! Galmed Pharmaceuticals Ltd's management wants to use your money to grow the business. In return you get a share of Galmed Pharmaceuticals Ltd.

What can you expect buying and holding a share of Galmed Pharmaceuticals Ltd?

First you should know what it really means to hold a share of Galmed Pharmaceuticals Ltd. And how you can make/lose money.

Speculation

The Price per Share of Galmed Pharmaceuticals Ltd is $0.3302. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Galmed Pharmaceuticals Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Galmed Pharmaceuticals Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.49. Based on the TTM, the Book Value Change Per Share is $-0.36 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.37 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Galmed Pharmaceuticals Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.24-71.4%-0.44-132.4%-1.01-306.3%-1.26-382.3%-1.25-378.8%
Usd Book Value Change Per Share-0.14-43.9%-0.36-109.1%-1.37-414.3%-1.01-305.3%0.0722.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.14-43.9%-0.36-109.1%-1.37-414.3%-1.01-305.3%0.0722.6%
Usd Price Per Share0.62-1.13-1.09-3.30-5.35-
Price to Earnings Ratio-0.66--0.74--0.59--0.82--1.76-
Price-to-Total Gains Ratio-4.28--3.67--0.12--3.20--6.46-
Price to Book Ratio0.25-0.42-0.48-0.36-0.96-
Price-to-Total Gains Ratio-4.28--3.67--0.12--3.20--6.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.3302
Number of shares3028
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.36-1.01
Usd Total Gains Per Share-0.36-1.01
Gains per Quarter (3028 shares)-1,091.22-3,052.12
Gains per Year (3028 shares)-4,364.86-12,208.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4365-43750-12208-12218
20-8730-87400-24417-24426
30-13095-131050-36625-36634
40-17459-174700-48834-48842
50-21824-218350-61042-61050
60-26189-262000-73251-73258
70-30554-305650-85459-85466
80-34919-349300-97668-97674
90-39284-392950-109876-109882
100-43649-436600-122085-122090

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.042.01.02.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%8.032.00.020.0%8.033.03.018.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%8.032.00.020.0%8.033.03.018.2%

Fundamentals of Galmed Pharmaceuticals Ltd

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Fundamental data was last updated by Penke on 2024-03-20 19:13:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Galmed Pharmaceuticals Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Galmed Pharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Galmed Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-34.4%+34.4%
5Y-34.4%10Y-274.0%+239.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY--262.1%+262.1%
5Y-34.4%-455.6%+421.2%
10Y-274.0%-589.0%+315.0%
1.1.2. Return on Assets

Shows how efficient Galmed Pharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Galmed Pharmaceuticals Ltd to the Biotechnology industry mean.
  • -8.4% Return on Assets means that Galmed Pharmaceuticals Ltd generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is -8.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.4%TTM-12.2%+3.8%
TTM-12.2%YOY-20.6%+8.4%
TTM-12.2%5Y-12.8%+0.7%
5Y-12.8%10Y-243.1%+230.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.4%-12.5%+4.1%
TTM-12.2%-12.2%+0.0%
YOY-20.6%-11.2%-9.4%
5Y-12.8%-13.4%+0.6%
10Y-243.1%-14.7%-228.4%
1.1.3. Return on Equity

Shows how efficient Galmed Pharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Galmed Pharmaceuticals Ltd to the Biotechnology industry mean.
  • -9.5% Return on Equity means Galmed Pharmaceuticals Ltd generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is -9.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM-14.9%+5.4%
TTM-14.9%YOY-25.3%+10.4%
TTM-14.9%5Y-15.1%+0.3%
5Y-15.1%10Y-16.5%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.5%-15.8%+6.3%
TTM-14.9%-15.7%+0.8%
YOY-25.3%-13.9%-11.4%
5Y-15.1%-18.3%+3.2%
10Y-16.5%-19.2%+2.7%

1.2. Operating Efficiency of Galmed Pharmaceuticals Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Galmed Pharmaceuticals Ltd is operating .

  • Measures how much profit Galmed Pharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Galmed Pharmaceuticals Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-39.0%+39.0%
5Y-39.0%10Y-278.6%+239.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY--279.7%+279.7%
5Y-39.0%-459.9%+420.9%
10Y-278.6%-596.9%+318.3%
1.2.2. Operating Ratio

Measures how efficient Galmed Pharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.390-0.390
5Y0.39010Y5.761-5.370
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY-3.615-3.615
5Y0.3905.560-5.170
10Y5.7617.396-1.635

1.3. Liquidity of Galmed Pharmaceuticals Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Galmed Pharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.79 means the company has $6.79 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is 6.790. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.931. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.790TTM4.931+1.859
TTM4.931YOY6.203-1.272
TTM4.9315Y11.881-6.950
5Y11.88110Y13.502-1.620
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7903.986+2.804
TTM4.9314.440+0.491
YOY6.2035.552+0.651
5Y11.8816.158+5.723
10Y13.5026.492+7.010
1.3.2. Quick Ratio

Measures if Galmed Pharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Galmed Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 12.39 means the company can pay off $12.39 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is 12.393. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.896. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.393TTM8.896+3.497
TTM8.896YOY11.428-2.532
TTM8.8965Y20.744-11.849
5Y20.74410Y21.632-0.888
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.3933.638+8.755
TTM8.8964.168+4.728
YOY11.4285.515+5.913
5Y20.7446.012+14.732
10Y21.6326.209+15.423

1.4. Solvency of Galmed Pharmaceuticals Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Galmed Pharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Galmed Pharmaceuticals Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Galmed Pharmaceuticals Ltd assets are financed with 11.9% credit (debt) and the remaining percentage (100% - 11.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is 0.119. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.176. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.119TTM0.176-0.057
TTM0.176YOY0.175+0.000
TTM0.1765Y0.125+0.051
5Y0.12510Y0.452-0.327
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1190.335-0.216
TTM0.1760.330-0.154
YOY0.1750.267-0.092
5Y0.1250.367-0.242
10Y0.4520.378+0.074
1.4.2. Debt to Equity Ratio

Measures if Galmed Pharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Galmed Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.4% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Galmed Pharmaceuticals Ltd:

  • The MRQ is 0.134. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.215. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.134TTM0.215-0.080
TTM0.215YOY0.216-0.001
TTM0.2155Y0.148+0.067
5Y0.14810Y0.169-0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1340.376-0.242
TTM0.2150.398-0.183
YOY0.2160.334-0.118
5Y0.1480.429-0.281
10Y0.1690.476-0.307

2. Market Valuation of Galmed Pharmaceuticals Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Galmed Pharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare Galmed Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A PE ratio of -0.66 means the investor is paying $-0.66 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Galmed Pharmaceuticals Ltd:

  • The EOD is -0.350. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.657. Based on the earnings, the company is expensive. -2
  • The TTM is -0.740. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.350MRQ-0.657+0.307
MRQ-0.657TTM-0.740+0.083
TTM-0.740YOY-0.588-0.153
TTM-0.7405Y-0.820+0.079
5Y-0.82010Y-1.759+0.940
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.350-2.643+2.293
MRQ-0.657-2.418+1.761
TTM-0.740-2.742+2.002
YOY-0.588-4.123+3.535
5Y-0.820-6.257+5.437
10Y-1.759-6.478+4.719
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Galmed Pharmaceuticals Ltd:

  • The EOD is -0.237. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.445. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.753. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.237MRQ-0.445+0.208
MRQ-0.445TTM-0.753+0.308
TTM-0.753YOY-0.518-0.235
TTM-0.7535Y-0.929+0.176
5Y-0.92910Y-2.075+1.146
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.237-3.244+3.007
MRQ-0.445-2.939+2.494
TTM-0.753-3.478+2.725
YOY-0.518-5.592+5.074
5Y-0.929-8.473+7.544
10Y-2.075-8.881+6.806
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Galmed Pharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.25 means the investor is paying $0.25 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Galmed Pharmaceuticals Ltd:

  • The EOD is 0.133. Based on the equity, the company is cheap. +2
  • The MRQ is 0.249. Based on the equity, the company is cheap. +2
  • The TTM is 0.419. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.133MRQ0.249-0.116
MRQ0.249TTM0.419-0.170
TTM0.419YOY0.478-0.059
TTM0.4195Y0.357+0.062
5Y0.35710Y0.959-0.602
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.1332.124-1.991
MRQ0.2492.041-1.792
TTM0.4192.118-1.699
YOY0.4782.915-2.437
5Y0.3573.682-3.325
10Y0.9594.114-3.155
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Galmed Pharmaceuticals Ltd.

3.1. Institutions holding Galmed Pharmaceuticals Ltd

Institutions are holding 14.156% of the shares of Galmed Pharmaceuticals Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Walleye Trading Advisors, LLC6.23340.00042497632497630
2023-09-30CVI Holdings LLC6.2240.30562493842493840
2023-09-30Two Sigma Advisers, LLC1.26370.000150633506330
2023-09-30Citadel Advisors Llc1.0097040458404580
2023-09-30Two Sigma Investments LLC0.76670.000130720307200
2023-09-30Virtu Financial LLC0.73890.001829608296080
2023-09-30Millennium Management LLC0.5024020130522235.0282
2023-09-30Morgan Stanley - Brokerage Accounts0.4999020032753460.2816
2023-09-30Wells Fargo & Co0.0051020400
2023-09-30TSFG, LLC0.0050.000420000
2023-09-30Advisor Group Holdings, Inc.0.0013053530
2023-09-30Bourgeon Capital Management LLC0.000803400
2023-09-30UBS Group AG0.0007028272700
2023-09-30Hanson Mcclain Inc0.000401700
2023-09-30ZRC WEALTH MANAGEMENT, LLC0.00020700
2023-09-30Bank of America Corp00220
2023-09-30Bvf Inc000-89853-100
2023-09-30Susquehanna International Group, LLP000-25597-100
2023-09-30Tower Research Capital LLC000-51-100
Total 17.25220.3084691273+547903+79.3%

3.2. Funds holding Galmed Pharmaceuticals Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Delaware Healthcare I0.50920.0012040100
2023-12-31Vifag 2002 SICAV0.18170.0057728200
2024-01-31Fidelity Nasdaq Composite Index0.04520181300
2023-09-30Blackstone Alternative Multi-Strategy I0.012505005000
Total 0.74860.006729996+500+1.7%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Galmed Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.145-0.360+149%-1.368+844%-1.008+595%0.075-294%
Book Value Per Share--2.4892.866-13%4.482-44%10.940-77%8.787-72%
Current Ratio--6.7904.931+38%6.203+9%11.881-43%13.502-50%
Debt To Asset Ratio--0.1190.176-32%0.175-32%0.125-5%0.452-74%
Debt To Equity Ratio--0.1340.215-37%0.216-38%0.148-9%0.169-20%
Dividend Per Share----0%-0%-0%-0%
Eps---0.236-0.437+85%-1.011+329%-1.262+435%-1.251+430%
Free Cash Flow Per Share---0.349-0.529+52%-1.069+207%-1.187+240%-0.909+161%
Free Cash Flow To Equity Per Share--0.642-0.282+144%-1.055+264%-0.679+206%1.081-41%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--27.990--------
Intrinsic Value_10Y_min---38.577--------
Intrinsic Value_1Y_max---2.708--------
Intrinsic Value_1Y_min---4.788--------
Intrinsic Value_3Y_max---3.935--------
Intrinsic Value_3Y_min---13.672--------
Intrinsic Value_5Y_max---0.097--------
Intrinsic Value_5Y_min---21.707--------
Market Cap1323055.266-193%3872636.5604891346.564-21%13970684.373-72%15201888.762-75%22419303.599-83%
Net Profit Margin----0%-0%-0.3440%-2.7400%
Operating Margin----0%-0%-0.3900%-2.7860%
Operating Ratio----0%-0%0.390-100%5.761-100%
Pb Ratio0.133-88%0.2490.419-41%0.478-48%0.357-30%0.959-74%
Pe Ratio-0.350+47%-0.657-0.740+13%-0.588-11%-0.820+25%-1.759+168%
Price Per Share0.330-88%0.6201.134-45%1.093-43%3.298-81%5.347-88%
Price To Free Cash Flow Ratio-0.237+47%-0.445-0.753+69%-0.518+16%-0.929+109%-2.075+367%
Price To Total Gains Ratio-2.278+47%-4.277-3.668-14%-0.123-97%-3.201-25%-6.459+51%
Quick Ratio--12.3938.896+39%11.428+8%20.744-40%21.632-43%
Return On Assets---0.084-0.122+46%-0.206+146%-0.128+54%-2.431+2811%
Return On Equity---0.095-0.149+57%-0.253+167%-0.151+60%-0.165+74%
Total Gains Per Share---0.145-0.360+149%-1.368+844%-1.008+595%0.075-294%
Usd Book Value--15547000.00012878500.000+21%24363750.000-36%45394150.000-66%35989225.000-57%
Usd Book Value Change Per Share---0.145-0.360+149%-1.368+844%-1.008+595%0.075-294%
Usd Book Value Per Share--2.4892.866-13%4.482-44%10.940-77%8.787-72%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.236-0.437+85%-1.011+329%-1.262+435%-1.251+430%
Usd Free Cash Flow---2177000.000-2316000.000+6%-5752500.000+164%-5087650.000+134%-3809250.000+75%
Usd Free Cash Flow Per Share---0.349-0.529+52%-1.069+207%-1.187+240%-0.909+161%
Usd Free Cash Flow To Equity Per Share--0.642-0.282+144%-1.055+264%-0.679+206%1.081-41%
Usd Market Cap1323055.266-193%3872636.5604891346.564-21%13970684.373-72%15201888.762-75%22419303.599-83%
Usd Price Per Share0.330-88%0.6201.134-45%1.093-43%3.298-81%5.347-88%
Usd Profit---1473000.000-1888250.000+28%-6003500.000+308%-5476000.000+272%-4497750.000+205%
Usd Revenue----0%-0%26900.000-100%103200.000-100%
Usd Total Gains Per Share---0.145-0.360+149%-1.368+844%-1.008+595%0.075-294%
 EOD+3 -5MRQTTM+21 -8YOY+21 -85Y+19 -1210Y+14 -17

4.2. Fundamental Score

Let's check the fundamental score of Galmed Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.350
Price to Book Ratio (EOD)Between0-10.133
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than112.393
Current Ratio (MRQ)Greater than16.790
Debt to Asset Ratio (MRQ)Less than10.119
Debt to Equity Ratio (MRQ)Less than10.134
Return on Equity (MRQ)Greater than0.15-0.095
Return on Assets (MRQ)Greater than0.05-0.084
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Galmed Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.521
Ma 20Greater thanMa 500.349
Ma 50Greater thanMa 1000.363
Ma 100Greater thanMa 2000.379
OpenGreater thanClose0.320
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Net Interest Income  30270300-128172106278-283-5



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets17,638
Total Liabilities2,091
Total Stockholder Equity15,547
 As reported
Total Liabilities 2,091
Total Stockholder Equity+ 15,547
Total Assets = 17,638

Assets

Total Assets17,638
Total Current Assets14,198
Long-term Assets3,440
Total Current Assets
Cash And Cash Equivalents 1,482
Short-term Investments 11,831
Net Receivables 770
Inventory -1,806
Other Current Assets 1,921
Total Current Assets  (as reported)14,198
Total Current Assets  (calculated)14,198
+/-0
Long-term Assets
Property Plant Equipment 175
Long Term Investments 3,265
Long-term Assets  (as reported)3,440
Long-term Assets  (calculated)3,440
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,091
Long-term Liabilities0
Total Stockholder Equity15,547
Total Current Liabilities
Accounts payable 1,474
Other Current Liabilities 617
Total Current Liabilities  (as reported)2,091
Total Current Liabilities  (calculated)2,091
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock166
Retained Earnings -190,936
Accumulated Other Comprehensive Income -607
Other Stockholders Equity 206,924
Total Stockholder Equity (as reported)15,547
Total Stockholder Equity (calculated)15,547
+/-0
Other
Capital Stock166
Cash and Short Term Investments 13,313
Common Stock Shares Outstanding 6,246
Liabilities and Stockholders Equity 17,638
Net Debt -1,482
Net Invested Capital 15,547
Net Working Capital 12,107
Property Plant and Equipment Gross 175



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
762
0
0
0
166
39,881
37,484
36,184
32,925
31,048
29,110
26,573
24,263
21,081
18,001
19,464
16,450
12,654
10,027
9,677
19,643
16,300
94,847
92,887
90,600
87,836
85,111
81,352
77,139
70,439
64,849
59,953
52,381
60,377
52,325
44,298
36,605
36,605
23,575
20,869
16,561
14,791
13,277
17,638
17,63813,27714,79116,56120,86923,57536,60536,60544,29852,32560,37752,38159,95364,84970,43977,13981,35285,11187,83690,60092,88794,84716,30019,6439,67710,02712,65416,45019,46418,00121,08124,26326,57329,11031,04832,92536,18437,48439,881166000762
   > Total Current Assets 
0
0
0
0
153
39,863
37,460
35,409
32,151
30,275
28,195
25,671
23,380
20,222
17,161
18,673
15,732
11,989
9,421
9,129
19,152
15,867
94,473
92,603
90,406
86,979
84,328
80,628
76,430
69,792
64,211
59,340
51,811
59,702
51,665
43,692
36,054
36,054
23,130
20,478
14,724
12,834
9,786
14,198
14,1989,78612,83414,72420,47823,13036,05436,05443,69251,66559,70251,81159,34064,21169,79276,43080,62884,32886,97990,40692,60394,47315,86719,1529,1299,42111,98915,73218,67317,16120,22223,38025,67128,19530,27532,15135,40937,46039,8631530000
       Cash And Cash Equivalents 
718
0
0
0
137
39,769
37,399
35,342
23,736
2,340
7,324
4,463
4,156
3,084
2,946
7,035
3,097
1,660
1,747
2,614
13,021
2,631
6,151
25,983
24,159
37,338
25,778
18,291
15,931
13,316
5,553
16,648
6,947
13,385
7,923
3,490
2,884
2,884
1,980
4,061
2,016
1,672
1,009
1,482
1,4821,0091,6722,0164,0611,9802,8842,8843,4907,92313,3856,94716,6485,55313,31615,93118,29125,77837,33824,15925,9836,1512,63113,0212,6141,7471,6603,0977,0352,9463,0844,1564,4637,3242,34023,73635,34237,39939,769137000718
       Short-term Investments 
0
0
0
0
0
0
0
0
8,250
27,547
20,486
20,862
18,845
16,882
13,736
11,272
12,351
9,993
7,408
6,344
5,976
12,871
87,954
66,334
66,029
49,224
57,845
61,439
59,560
55,573
57,876
41,937
43,939
45,420
43,142
38,415
31,931
31,931
20,422
15,152
11,769
10,480
8,321
11,831
11,8318,32110,48011,76915,15220,42231,93131,93138,41543,14245,42043,93941,93757,87655,57359,56061,43957,84549,22466,02966,33487,95412,8715,9766,3447,4089,99312,35111,27213,73616,88218,84520,86220,48627,5478,25000000000
       Net Receivables 
0
0
0
0
11
94
61
67
64
388
385
346
379
256
479
366
284
336
266
171
155
365
368
286
51
417
705
898
226
790
669
642
66
784
487
1,674
79
79
614
1,151
124
568
341
770
7703415681241,15161479791,674487784666426697902268987054175128636836515517126633628436647925637934638538864676194110000
       Inventory 
0
0
0
0
0
0
-180
0
-5,899
-6,000
0
0
-270
0
0
0
-254
0
0
0
-100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
114
113
0
-1,806
-1,80601131140000000000000000000-100000-254000-27000-6,000-5,8990-180000000
   > Long-term Assets 
0
0
0
0
13
18
24
775
774
773
915
902
883
859
840
791
718
665
606
548
491
433
374
284
194
857
783
724
709
647
638
613
570
675
660
606
551
551
445
391
1,837
1,957
3,491
3,440
3,4403,4911,9571,8373914455515516066606755706136386477097247838571942843744334915486066657187918408598839029157737747752418130000
       Property Plant Equipment 
30
0
0
0
13
18
24
775
774
773
915
902
883
859
840
791
718
665
606
548
491
433
374
284
194
857
783
724
709
647
638
613
570
675
660
606
551
551
445
391
337
281
226
175
17522628133739144555155160666067557061363864770972478385719428437443349154860666571879184085988390291577377477524181300030
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,500
1,676
3,265
3,265
3,2653,2651,6761,5000000000000000000000000000000000000000000
> Total Liabilities 
2,741
0
0
0
2,117
1,928
1,136
2,933
1,518
1,561
1,695
1,513
2,718
3,201
3,575
3,934
5,375
4,356
3,785
3,145
3,848
2,698
3,804
2,139
2,706
2,908
3,724
3,929
7,286
6,335
4,965
6,297
8,228
7,420
7,326
6,622
6,108
6,108
2,863
5,120
3,138
2,801
2,723
2,091
2,0912,7232,8013,1385,1202,8636,1086,1086,6227,3267,4208,2286,2974,9656,3357,2863,9293,7242,9082,7062,1393,8042,6983,8483,1453,7854,3565,3753,9343,5753,2012,7181,5131,6951,5611,5182,9331,1361,9282,1170002,741
   > Total Current Liabilities 
513
0
0
0
1,689
1,498
694
2,565
1,118
1,356
1,501
1,326
2,541
3,024
3,353
2,860
4,579
3,819
3,635
2,995
3,848
2,698
3,804
2,139
2,706
2,409
3,282
3,540
6,934
6,033
4,714
6,050
8,012
7,137
7,008
6,348
5,879
5,879
2,729
5,031
3,094
2,801
2,723
2,091
2,0912,7232,8013,0945,0312,7295,8795,8796,3487,0087,1378,0126,0504,7146,0336,9343,5403,2822,4092,7062,1393,8042,6983,8482,9953,6353,8194,5792,8603,3533,0242,5411,3261,5011,3561,1182,5656941,4981,689000513
       Accounts payable 
401
0
0
0
1,355
1,100
301
1,997
875
1,147
1,229
1,126
2,259
2,951
2,965
1,703
3,122
2,538
2,365
1,965
2,276
2,196
2,346
1,288
1,814
1,797
2,578
2,742
5,999
5,330
3,876
5,151
7,046
5,803
5,629
5,233
4,871
4,871
2,089
4,749
2,560
2,266
2,140
1,474
1,4742,1402,2662,5604,7492,0894,8714,8715,2335,6295,8037,0465,1513,8765,3305,9992,7422,5781,7971,8141,2882,3462,1962,2761,9652,3652,5383,1221,7032,9652,9512,2591,1261,2291,1478751,9973011,1001,355000401
       Other Current Liabilities 
92
0
0
0
334
398
393
568
243
209
272
200
282
73
388
112
363
196
185
219
1,034
232
1,458
851
892
612
704
798
935
703
838
899
966
1,334
1,379
1,115
1,008
1,008
640
282
534
535
583
617
6175835355342826401,0081,0081,1151,3791,3349668998387039357987046128928511,4582321,0342191851963631123887328220027220924356839339833400092
   > Long-term Liabilities 
0
0
0
0
428
430
442
368
400
205
194
187
177
177
222
1,074
796
537
150
150
0
0
0
0
0
499
442
389
352
302
251
247
216
283
318
274
229
229
134
89
44
2,266
0
0
002,2664489134229229274318283216247251302352389442499000001501505377961,0742221771771871942054003684424304280000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
499
442
389
352
302
251
247
216
283
318
274
229
183
134
89
44
0
0
0
00044891341832292743182832162472513023523894424990000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
499
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000004990000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
529
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000005290000000000000000
> Total Stockholder Equity
0
0
0
0
-1,951
37,953
36,348
33,251
31,407
29,487
27,415
25,060
21,545
17,880
14,426
15,530
11,075
8,298
6,242
6,532
15,795
13,602
91,043
90,748
87,894
84,928
81,387
77,423
69,853
64,104
59,884
53,656
44,153
52,957
44,999
37,676
30,497
30,497
20,712
15,749
13,423
11,990
10,554
15,547
15,54710,55411,99013,42315,74920,71230,49730,49737,67644,99952,95744,15353,65659,88464,10469,85377,42381,38784,92887,89490,74891,04313,60215,7956,5326,2428,29811,07515,53014,42617,88021,54525,06027,41529,48731,40733,25136,34837,953-1,9510000
   Retained Earnings -190,936-189,463-187,870-186,040-183,401-178,051-168,174-168,174-160,722-153,008-144,612-135,707-125,430-118,525-112,999-106,936-98,650-94,136-89,967-86,475-82,769-81,810-79,125-76,619-72,975-70,174-67,482-64,320-59,494-55,662-51,351-47,367-44,162-41,562-39,208-36,745-34,766-31,560-29,803-27,6420000
   Accumulated Other Comprehensive Income 
0
0
0
0
-17
0
0
0
4
-11
-61
-56
-206
-160
-104
-135
-85
-61
-20
-8
-7
-36
-29
-10
-11
25
41
52
35
-227
498
90
272
142
108
-75
-171
-171
-982
-876
-745
-645
-662
-607
-607-662-645-745-876-982-171-171-7510814227290498-22735524125-11-10-29-36-7-8-20-61-85-135-104-160-206-56-61-114000-170000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
174,322
174,812
175,424
175,963
176,696
177,272
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000177,272176,696175,963175,424174,812174,322000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-7,790
Operating Income-7,790-7,790
 
Operating Expense (+$)
Research Development3,826
Selling General Administrative3,964
Selling And Marketing Expenses-
Operating Expense7,7907,790
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-745
Net Interest Income745
 
Pretax Income (+$)
Operating Income-7,790
Net Interest Income745
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-7,535-7,790
EBIT - interestExpense = 0
-7,535
-7,535
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--7,535
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-7,535
Tax Provision--
Net Income From Continuing Ops-7,535-7,535
Net Income-7,535
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--745
 

Technical Analysis of Galmed Pharmaceuticals Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Galmed Pharmaceuticals Ltd. The general trend of Galmed Pharmaceuticals Ltd is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Galmed Pharmaceuticals Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Galmed Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.34 < 0.34 < 0.35.

The bearish price targets are: 0.3 > 0.3 > 0.26.

Tweet this
Galmed Pharmaceuticals Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Galmed Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Galmed Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Galmed Pharmaceuticals Ltd. The current macd is -0.01650477.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Galmed Pharmaceuticals Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Galmed Pharmaceuticals Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Galmed Pharmaceuticals Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Galmed Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGalmed Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Galmed Pharmaceuticals Ltd. The current adx is 19.20.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Galmed Pharmaceuticals Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Galmed Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Galmed Pharmaceuticals Ltd. The current sar is 0.39744266.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Galmed Pharmaceuticals Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Galmed Pharmaceuticals Ltd. The current rsi is 43.52. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Galmed Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartGalmed Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Galmed Pharmaceuticals Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Galmed Pharmaceuticals Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Galmed Pharmaceuticals Ltd Daily Stochastic Oscillator ChartGalmed Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Galmed Pharmaceuticals Ltd. The current cci is -49.95943055.

Galmed Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartGalmed Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Galmed Pharmaceuticals Ltd. The current cmo is -8.10457978.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Galmed Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartGalmed Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Galmed Pharmaceuticals Ltd. The current willr is -72.54545455.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Galmed Pharmaceuticals Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Galmed Pharmaceuticals Ltd Daily Williams %R ChartGalmed Pharmaceuticals Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Galmed Pharmaceuticals Ltd. The current atr is 0.03175759.

Galmed Pharmaceuticals Ltd Daily Average True Range (ATR) ChartGalmed Pharmaceuticals Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Galmed Pharmaceuticals Ltd. The current obv is -6,304,619.

Galmed Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartGalmed Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Galmed Pharmaceuticals Ltd. The current mfi is 7.25728601.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Galmed Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartGalmed Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Galmed Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Galmed Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Galmed Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.521
Ma 20Greater thanMa 500.349
Ma 50Greater thanMa 1000.363
Ma 100Greater thanMa 2000.379
OpenGreater thanClose0.320
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Galmed Pharmaceuticals Ltd with someone you think should read this too:
  • Are you bullish or bearish on Galmed Pharmaceuticals Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Galmed Pharmaceuticals Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Galmed Pharmaceuticals Ltd

I send you an email if I find something interesting about Galmed Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Galmed Pharmaceuticals Ltd.

Receive notifications about Galmed Pharmaceuticals Ltd in your mailbox!